These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 704765)

  • 21. Trial rights and psychotropic drugs: the case against administering involuntary medications to a defendant during trial.
    Klein DW
    Vanderbilt Law Rev; 2002; 55(1):165-218. PubMed ID: 12680366
    [No Abstract]   [Full Text] [Related]  

  • 22. Psychotropic medication of mentally retarded residents in community long-term care facilities.
    Buck JA; Sprague RL
    Am J Ment Retard; 1989 May; 93(6):618-23. PubMed ID: 2566316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A clinical pharmacy service to reduce psychotropic medication use in an institution for mentally handicapped persons.
    Inoue F
    Ment Retard; 1982 Apr; 20(2):70-4. PubMed ID: 7078402
    [No Abstract]   [Full Text] [Related]  

  • 24. Pilot study on the use of psychotropic medication in persons with mental retardation.
    Radouco-Thomas M; Bolduc M; Brisson A; Brassard P; Fortier L; Thivierge J
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Aug; 28(5):879-83. PubMed ID: 15363610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [How should mentally handicapped adults with depressive disorders be treated psychopharmacologically?].
    Meins W
    Nervenarzt; 1996 Mar; 67(3):216-8. PubMed ID: 8901279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Issues and future research directions of pharmacotherapy in mental retardation.
    Schroeder SR
    Psychopharmacol Bull; 1985; 21(2):323-6. PubMed ID: 4001293
    [No Abstract]   [Full Text] [Related]  

  • 27. Results of a system to monitor effects of psychotropic medication in an applied setting.
    Kalachnik JE; Miller RF; Jamison AG; Harder SR
    Psychopharmacol Bull; 1983; 19(1):12-5. PubMed ID: 6828619
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacologic management of psychiatric and behavioral symptoms in mental retardation.
    Madrid AL; State MW; King BH
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):225-43, x-xi. PubMed ID: 10674198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of interdisciplinary team review on the use of antipsychotic agents with severely and profoundly mentally retarded persons.
    Glaser BA; Morreau LE
    Am J Ment Defic; 1986 Jan; 90(4):371-9. PubMed ID: 3946474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Looking backwards: a possible new path for drug discovery in psychopharmacology.
    Shorter E
    Nat Rev Drug Discov; 2002 Dec; 1(12):1003-6. PubMed ID: 12461521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people.
    Hill BK; Balow EA; Bruininks RH
    Psychopharmacol Bull; 1985; 21(2):279-84. PubMed ID: 4001292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Boston State Hospital case: its impact on the handling of future mental health litigation.
    Schultz S
    Bull Am Acad Psychiatry Law; 1980; 8(3):345-51. PubMed ID: 7284610
    [No Abstract]   [Full Text] [Related]  

  • 33. [History and advances in current psychopharmacology].
    Płaźnik A; Kostowski W; Puciłowski O
    Pol Tyg Lek; 1983 Dec 19-26; 38(51-52):1633-7. PubMed ID: 6382205
    [No Abstract]   [Full Text] [Related]  

  • 34. Implementation of an interdisciplinary psychotropic drug review process for community-based facilities.
    Lepler S; Hodas A; Cotter-Mack A
    Ment Retard; 1993 Oct; 31(5):307-15. PubMed ID: 8271941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of states' practices on the use of psychotropic medication.
    Rinck C; Guidry J; Calkins CF
    Am J Ment Retard; 1989 May; 93(6):657-68. PubMed ID: 2719848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication and programming in controlling the behavior of mentally retarded individuals in community settings.
    Schalock RL; Foley JW; Toulouse A; Stark JA
    Am J Ment Defic; 1985 Mar; 89(5):503-9. PubMed ID: 2859807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DSM-III-R and pediatric psychopharmacology.
    Rapoport JL
    Psychopharmacol Bull; 1985; 21(4):803-6. PubMed ID: 3911250
    [No Abstract]   [Full Text] [Related]  

  • 38. [Use of psychotropic medication among individuals with mental retardation].
    Baasland G; Engedal K
    Tidsskr Nor Laegeforen; 2009 Sep; 129(17):1751-3. PubMed ID: 19756056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medicine. What are the right targets for psychopharmacology?
    Hyman SE; Fenton WS
    Science; 2003 Jan; 299(5605):350-1. PubMed ID: 12532001
    [No Abstract]   [Full Text] [Related]  

  • 40. The National Institute of Mental Health-Psychotherapeutic Medications Development Program (PMDP): status 1993.
    Haigler HJ
    Psychopharmacol Bull; 1994; 30(1):19-22. PubMed ID: 7972624
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.